For patients with atrial fibrillation undergoing PCI, double therapy with a NOAC and P2Y12 inhibitor is the standard of care, minimizing the duration of triple therapy to reduce bleeding risk.
inhibitor, preferably clopidogrel, in combination with a non-vitamin K antagonist oral anticoagulant (ie, double therapy). In patients at increased thrombotic risk who have an acceptable risk of bleeding, it is reasonable to continue aspirin (ie, triple therapy) for up to 1 month. Double therapy should be given for 6 to 12 months with the actual duration depending on the ischemic and bleeding risk profile of the patient, after which patients should discontinue antiplatelet therapy and receive oral anticoagulation alone.
Angiolillo et al. (Mon,) studied this question.